Scientists have discovered a new therapy that ”helps very ill Coronavirus patients recover in 72 hours.
Researchers say they have evidence that seriously ill coronavirus patients can benefit from infusions of blood plasma collected from people who have recovered from the disease and permission has now been given to University Hospital Erlangen, Germany, to produce therapeutic plasma to treat critically ill Covid-19 patients.
Doctors in China gave antibody-rich plasma from recovered patients to 15 severely Coronavirus ill patients and recorded striking improvements in many of them within three days.
According to theguardian.com, “Another team of doctors led by Lei Liu, from Shenzhen Third People’s hospital, gave convalescent plasma to five critically ill patients. All showed improved symptoms after the infusions and within 10 days, three patients were able to come off the ventilators that had been keeping them alive, according to a preliminary report in the Journal of the American Medical Association.
The therapy known as Convalescent plasma treatments, dates back to the 1918 Spanish flu pandemic. The therapy thrives on the the premise that people who have recovered from a viral infection have antibodies in their blood that can rapidly detect and destroy the virus the next time it attacks.
Professor David Tappin, a senior research fellow at the University of Glasgow, has applied to the UK’s National Institute for Health Research to run two clinical trials with convalescent plasma.
He said the outcomes are also encouraging for the patients but that to be sure plasma improved on the natural course of the disease, and that it was safe in larger groups of patients, formal trials had to take place.
Professor Munir Pirmohamed, the president of the British Pharmacological Society, says the treatment should be carefully examined.
He clarified that this was not a randomised trial and that all patients also received other treatments including antivirals such as remdesivir, which are currently in trials for Covid-19.
He added that: “It is also important to remember that there are potential safety concerns with convalescent plasma, including transmission of other agents and antibody enhancement of disease. Even if shown to work, scalability to treat large numbers of patients may become an issue.”
